10 Einträge von 322 mit therapy inhibitors
www.cslbehring.ch
Datum der Indexierung 21.01.2024 21:23:06
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords studies through | behring investigator-initiated | with nouvelles | that plus | disease notre | nous research | initiated including | patients quality | clinical products | application investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Therapy Use of C1-INH in special patient populations (eg; pregnancy, pediatrics) Hematology We seek to advance science and improve patient care with CSL Behring’s products in the field of hematology. Through total or partial funding, we support exter inhibitors, Clazakizumab and Alpha-1 Antitrypsin in cell and organ transplantation. Specific Research Priorities include: Graft versus Host Disease (GvHD) following: Hematopoietic Cell Transplant (HCT) Burden of disease, natural c
Text Inhalt Text aus URL
Log Metriken 1036321
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords studies through | behring investigator-initiated | with nouvelles | that plus | disease notre | nous research | initiated including | patients quality | clinical products | application investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Therapy Use of C1-INH in special patient populations (eg; pregnancy, pediatrics) Hematology We seek to advance science and improve patient care with CSL Behring’s products in the field of hematology. Through total or partial funding, we support exter inhibitors, Clazakizumab and Alpha-1 Antitrypsin in cell and organ transplantation. Specific Research Priorities include: Graft versus Host Disease (GvHD) following: Hematopoietic Cell Transplant (HCT) Burden of disease, natural c
Text Inhalt Text aus URL
Log Metriken 1036321
www.cslbehring.ch
Datum der Indexierung 15.01.2024 02:32:16
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords studies through | behring investigator-initiated | with nouvelles | that plus | disease notre | nous research | initiated including | patients quality | clinical products | application investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Therapy Use of C1-INH in special patient populations (eg; pregnancy, pediatrics) Hematology We seek to advance science and improve patient care with CSL Behring’s products in the field of hematology. Through total or partial funding, we support exter inhibitors, Clazakizumab and Alpha-1 Antitrypsin in cell and organ transplantation. Specific Research Priorities include: Graft versus Host Disease (GvHD) following: Hematopoietic Cell Transplant (HCT) Burden of disease, natural c
Text Inhalt Text aus URL
Log Metriken 1036321
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords studies through | behring investigator-initiated | with nouvelles | that plus | disease notre | nous research | initiated including | patients quality | clinical products | application investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Therapy Use of C1-INH in special patient populations (eg; pregnancy, pediatrics) Hematology We seek to advance science and improve patient care with CSL Behring’s products in the field of hematology. Through total or partial funding, we support exter inhibitors, Clazakizumab and Alpha-1 Antitrypsin in cell and organ transplantation. Specific Research Priorities include: Graft versus Host Disease (GvHD) following: Hematopoietic Cell Transplant (HCT) Burden of disease, natural c
Text Inhalt Text aus URL
Log Metriken 1036321
www.cslbehring.ch
Datum der Indexierung 10.01.2024 05:07:55
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords studies through | behring investigator-initiated | with nouvelles | that plus | disease notre | nous research | initiated including | patients quality | clinical products | application investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Therapy Use of C1-INH in special patient populations (eg; pregnancy, pediatrics) Hematology We seek to advance science and improve patient care with CSL Behring’s products in the field of hematology. Through total or partial funding, we support exter inhibitors, Clazakizumab and Alpha-1 Antitrypsin in cell and organ transplantation. Specific Research Priorities include: Graft versus Host Disease (GvHD) following: Hematopoietic Cell Transplant (HCT) Burden of disease, natural c
Text Inhalt Text aus URL
Log Metriken 1036321
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords studies through | behring investigator-initiated | with nouvelles | that plus | disease notre | nous research | initiated including | patients quality | clinical products | application investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Therapy Use of C1-INH in special patient populations (eg; pregnancy, pediatrics) Hematology We seek to advance science and improve patient care with CSL Behring’s products in the field of hematology. Through total or partial funding, we support exter inhibitors, Clazakizumab and Alpha-1 Antitrypsin in cell and organ transplantation. Specific Research Priorities include: Graft versus Host Disease (GvHD) following: Hematopoietic Cell Transplant (HCT) Burden of disease, natural c
Text Inhalt Text aus URL
Log Metriken 1036321
www.cslbehring.ch
Datum der Indexierung 15.01.2024 02:34:08
erkannte Namen Ria STAP | Norbert Heimberger |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring drug | first deficiency | plasma switzerland | with plant | approved award | patients approval | treatment immunglobulin | factor bern | production market | company more |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
therapy in many areas of treatment. Learn More We also aim to make sure that nothing holds you back from getting the therapies you need. Learn More R&D R&D Investigator Initiated Studies Our product portfolio focuses on innovation in new products, im inhibitors, the country’s first and only way to treat acute phases of hereditary angioedema (HAE) in the abdomen or face. 2009 CSL Behring receives the Tell Award for Innovation CSL Behring was presented with the Swiss government’
Text Inhalt Text aus URL
Log Metriken 32759
erkannte Namen Ria STAP | Norbert Heimberger |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring drug | first deficiency | plasma switzerland | with plant | approved award | patients approval | treatment immunglobulin | factor bern | production market | company more |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
therapy in many areas of treatment. Learn More We also aim to make sure that nothing holds you back from getting the therapies you need. Learn More R&D R&D Investigator Initiated Studies Our product portfolio focuses on innovation in new products, im inhibitors, the country’s first and only way to treat acute phases of hereditary angioedema (HAE) in the abdomen or face. 2009 CSL Behring receives the Tell Award for Innovation CSL Behring was presented with the Swiss government’
Text Inhalt Text aus URL
Log Metriken 32759
www.cslbehring.ch
Datum der Indexierung 10.01.2024 05:09:40
erkannte Namen Ria STAP | Norbert Heimberger |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring drug | first deficiency | plasma switzerland | with plant | approved award | patients approval | treatment immunglobulin | factor bern | production market | company more |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
therapy in many areas of treatment. Learn More We also aim to make sure that nothing holds you back from getting the therapies you need. Learn More R&D R&D Investigator Initiated Studies Our product portfolio focuses on innovation in new products, im inhibitors, the country’s first and only way to treat acute phases of hereditary angioedema (HAE) in the abdomen or face. 2009 CSL Behring receives the Tell Award for Innovation CSL Behring was presented with the Swiss government’
Text Inhalt Text aus URL
Log Metriken 32759
erkannte Namen Ria STAP | Norbert Heimberger |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring drug | first deficiency | plasma switzerland | with plant | approved award | patients approval | treatment immunglobulin | factor bern | production market | company more |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
therapy in many areas of treatment. Learn More We also aim to make sure that nothing holds you back from getting the therapies you need. Learn More R&D R&D Investigator Initiated Studies Our product portfolio focuses on innovation in new products, im inhibitors, the country’s first and only way to treat acute phases of hereditary angioedema (HAE) in the abdomen or face. 2009 CSL Behring receives the Tell Award for Innovation CSL Behring was presented with the Swiss government’
Text Inhalt Text aus URL
Log Metriken 32759
www.cslbehring.ch
Datum der Indexierung 15.01.2024 02:34:58
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies learn | that diseases | disease research | products health | clinical your | initiated more | application patients | investigator quality |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
therapy in many areas of treatment. Learn More We also aim to make sure that nothing holds you back from getting the therapies you need. Learn More R&D R&D Investigator Initiated Studies Our product portfolio focuses on innovation in new products, im inhibitors, Clazakizumab and Alpha-1 Antitrypsin in cell and organ transplantation. Specific Research Priorities include: Graft versus Host Disease (GvHD) following: Hematopoietic Cell Transplant (HCT) Burden of disease, natural c
Text Inhalt Text aus URL
Log Metriken 1036330
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies learn | that diseases | disease research | products health | clinical your | initiated more | application patients | investigator quality |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
therapy in many areas of treatment. Learn More We also aim to make sure that nothing holds you back from getting the therapies you need. Learn More R&D R&D Investigator Initiated Studies Our product portfolio focuses on innovation in new products, im inhibitors, Clazakizumab and Alpha-1 Antitrypsin in cell and organ transplantation. Specific Research Priorities include: Graft versus Host Disease (GvHD) following: Hematopoietic Cell Transplant (HCT) Burden of disease, natural c
Text Inhalt Text aus URL
Log Metriken 1036330
www.cslbehring.ch
Datum der Indexierung 10.01.2024 05:10:09
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies learn | that diseases | disease research | products health | clinical your | initiated more | application patients | investigator quality |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
therapy in many areas of treatment. Learn More We also aim to make sure that nothing holds you back from getting the therapies you need. Learn More R&D R&D Investigator Initiated Studies Our product portfolio focuses on innovation in new products, im inhibitors, Clazakizumab and Alpha-1 Antitrypsin in cell and organ transplantation. Specific Research Priorities include: Graft versus Host Disease (GvHD) following: Hematopoietic Cell Transplant (HCT) Burden of disease, natural c
Text Inhalt Text aus URL
Log Metriken 1036330
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies learn | that diseases | disease research | products health | clinical your | initiated more | application patients | investigator quality |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
therapy in many areas of treatment. Learn More We also aim to make sure that nothing holds you back from getting the therapies you need. Learn More R&D R&D Investigator Initiated Studies Our product portfolio focuses on innovation in new products, im inhibitors, Clazakizumab and Alpha-1 Antitrypsin in cell and organ transplantation. Specific Research Priorities include: Graft versus Host Disease (GvHD) following: Hematopoietic Cell Transplant (HCT) Burden of disease, natural c
Text Inhalt Text aus URL
Log Metriken 1036330
www.cslbehring.ch
Datum der Indexierung 21.01.2024 21:26:51
erkannte Namen Gene Therapy | Emmanuelle Lecomte | Isabelle Dahinden | Maria Tortoreto |
weitere Namen in www.cslbehring.ch 4
Subdomain:
extern (outbound) Link/Domain 8 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Swissmedic Approval for HEMGENIX®
Kombination Keywords hemgenix global | patients disease | hemophilia this | factor products | with trial | treatment gene | behring from | more therapy | that learn | bleeding people |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
therapy in many areas of treatment. Learn More We also aim to make sure that nothing holds you back from getting the therapies you need. Learn More R&D R&D Investigator Initiated Studies Our product portfolio focuses on innovation in new products, im inhibitors to factor IX were reported. Long-term 36-month data presented at the 65th American Society of Hematology (ASH) 2023 Annual Meeting and Exposition continue to reinforce the potential long-lasting efficacy and safety of H
Text Inhalt Text aus URL
Log Metriken 1425713
erkannte Namen Gene Therapy | Emmanuelle Lecomte | Isabelle Dahinden | Maria Tortoreto |
weitere Namen in www.cslbehring.ch 4
Subdomain:
extern (outbound) Link/Domain 8 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Swissmedic Approval for HEMGENIX®
Kombination Keywords hemgenix global | patients disease | hemophilia this | factor products | with trial | treatment gene | behring from | more therapy | that learn | bleeding people |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
therapy in many areas of treatment. Learn More We also aim to make sure that nothing holds you back from getting the therapies you need. Learn More R&D R&D Investigator Initiated Studies Our product portfolio focuses on innovation in new products, im inhibitors to factor IX were reported. Long-term 36-month data presented at the 65th American Society of Hematology (ASH) 2023 Annual Meeting and Exposition continue to reinforce the potential long-lasting efficacy and safety of H
Text Inhalt Text aus URL
Log Metriken 1425713
www.cslbehring.ch
Datum der Indexierung 21.01.2024 21:25:21
erkannte Namen Ria STAP | Norbert Heimberger |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring drug | first deficiency | plasma switzerland | with plant | approved award | patients approval | treatment immunglobulin | factor bern | production market | company more |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
therapy in many areas of treatment. Learn More We also aim to make sure that nothing holds you back from getting the therapies you need. Learn More R&D R&D Investigator Initiated Studies Our product portfolio focuses on innovation in new products, im inhibitors, the country’s first and only way to treat acute phases of hereditary angioedema (HAE) in the abdomen or face. 2009 CSL Behring receives the Tell Award for Innovation CSL Behring was presented with the Swiss government’
Text Inhalt Text aus URL
Log Metriken 32759
erkannte Namen Ria STAP | Norbert Heimberger |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring drug | first deficiency | plasma switzerland | with plant | approved award | patients approval | treatment immunglobulin | factor bern | production market | company more |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
therapy in many areas of treatment. Learn More We also aim to make sure that nothing holds you back from getting the therapies you need. Learn More R&D R&D Investigator Initiated Studies Our product portfolio focuses on innovation in new products, im inhibitors, the country’s first and only way to treat acute phases of hereditary angioedema (HAE) in the abdomen or face. 2009 CSL Behring receives the Tell Award for Innovation CSL Behring was presented with the Swiss government’
Text Inhalt Text aus URL
Log Metriken 32759
www.cslbehring.ch
Datum der Indexierung 21.01.2024 21:25:55
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies learn | that diseases | disease research | products health | clinical your | initiated more | application patients | investigator quality |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
therapy in many areas of treatment. Learn More We also aim to make sure that nothing holds you back from getting the therapies you need. Learn More R&D R&D Investigator Initiated Studies Our product portfolio focuses on innovation in new products, im inhibitors, Clazakizumab and Alpha-1 Antitrypsin in cell and organ transplantation. Specific Research Priorities include: Graft versus Host Disease (GvHD) following: Hematopoietic Cell Transplant (HCT) Burden of disease, natural c
Text Inhalt Text aus URL
Log Metriken 1036330
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 9 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring areas | with including | studies learn | that diseases | disease research | products health | clinical your | initiated more | application patients | investigator quality |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
therapy in many areas of treatment. Learn More We also aim to make sure that nothing holds you back from getting the therapies you need. Learn More R&D R&D Investigator Initiated Studies Our product portfolio focuses on innovation in new products, im inhibitors, Clazakizumab and Alpha-1 Antitrypsin in cell and organ transplantation. Specific Research Priorities include: Graft versus Host Disease (GvHD) following: Hematopoietic Cell Transplant (HCT) Burden of disease, natural c
Text Inhalt Text aus URL
Log Metriken 1036330